Bristol Myers collaborating with Microsoft for early detection of lung cancer

Bristol Myers (BMY)announced an agreement with Microsoft (MSFT) aiming to accelerate early detection of lung cancer. Through this digital health collaboration, U.S. FDA-cleared radiology AI algorithms will be deployed via Microsoft’s Precision Imaging Network, part of Microsoft for Healthcare radiology solutions. These advanced AI algorithms can help surface hard to detect lung nodules, potentially identify patients at earlier stages of lung cancer, and help triage them for appropriate care. A core objective of the collaboration is to expand access to early detection in medically underserved communities, including rural hospitals and community clinics across the United States.